Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Retrospective Study of Adjuvant Chemotherapy Effects on Survival Rate after Three-Field Lymph Node Dissection for Stage IIA Esophageal Cancer

  • Chen, Hua-Xia (Department of Thoracic Surgery, Provincial Hospital Affiliated to Shandong University) ;
  • Wang, Zhou (Department of Thoracic Surgery, Provincial Hospital Affiliated to Shandong University)
  • Published : 2015.08.03
Download PDF
⟨ Previous Next ⟩

Abstract

To determine the efficacy of postoperative adjuvant chemotherapy with paclitaxel plus cisplatin (Taxol + DDP, TP therapy) for stage IIA esophageal squamous cell carcinoma (ESCC) and to investigate the expression of RUNX3 in lymph node metastasis-negative esophageal cancer and its relationship with medical prognosis, a retrospective summary of clinical treatment of 143 cases of stage IIA esophageal squamous cell carcinoma patients was made. The patients were divided into two groups, a surgery alone control group (52 patients) and a chemotherapy group that received postoperative TP therapy (91 patients). The disease-free and 5 year survival rates were compared between the groups and a multivariate analysis of prognostic factors was performed. The same analysis was performed for cases classified as RUNX3 positive and negative, with post-operative specimens assessed by immunohistochemistry. Although the disease-free and 5 year survival rates in control and chemotherapy groups did not significantly differ and there was no significance in RUNX3 negative cases, postoperative adjuvant chemotherapy in the chemotherapy group was shown to improve disease-free and 5 year survival rate compared to the control group in RUNX3 positive cases. On Cox regression multivariate analysis, postoperative adjuvant chemotherapy (P<0.01) was an independent prognostic factor for RUNX3 positive cases, suggesting that postoperative TP may be effective as adjuvant chemotherapy for stage IIA esophageal cancer patients with RUNX3 positive lesions.

Keywords

References

  1. Ando N, Iizuka T, Ide H, et al (2003). Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a japan clinical oncology group study. J Clin Oncol, 21, 4592-6. https://doi.org/10.1200/JCO.2003.12.095
  2. Araki K, Osaki M, Nagahama Y, et al (2005). Expression of RUNX3 protein in human lung adenocarcinoma: implications for tumor progression and prognosis. Cancer Sci, 96, 227-31. https://doi.org/10.1111/j.1349-7006.2005.00033.x
  3. Cho, M, Choi, E, Kim, J. H, et al (2014). Lactam-Based HDAC Inhibitors for Anticancer Chemotherapy: Restoration of RUNX3 by Posttranslational Modification and Epigenetic Control. Chem Med Chem, 9, 649-56. https://doi.org/10.1002/cmdc.201300393
  4. Fang WT, Chen WH (2009). Current trends in extended lymph node dissection for esophageal carcinom. Asian Cardiovasc Thorac Ann, 17, 208-13. https://doi.org/10.1177/0218492309103332
  5. Gao J, Chen Y, Wu KC, et al (2010). RUNX3 dir ectly interacts with intracellular domain of Notch1 and suppresses Notch signaling in hepatocellular carcinoma cells. Exp Cell Res, 316, 149-57. https://doi.org/10.1016/j.yexcr.2009.09.025
  6. Hiramatsu T, Osaki M, Ito Y, et al (2005). Expression of RUNX3 protein in human esophageal mucosa and squamous cell carcinoma. Pathobiol, 72, 316-24. https://doi.org/10.1159/000091329
  7. Hsu PI, Hsieh HL, Lee J, et al (2009). Loss of RUNX3 expression correlates with differentiation, nodal metastasis, and poor prognosis of gastric cancer. Ann Surg Oncol, 6, 1686-94.
  8. Ito K, Liu Q, Salto-Tellez M, et al (2005). RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. Cancer Res, 65, 7743-50.
  9. Jiang Y, Tong D, Lou G, et al (2008). Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines. Pathobiol, 75, 244-51. https://doi.org/10.1159/000132385
  10. Lau QC, Raja E, Salto-Tellez M, et al (2006). RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res, 66, 6512-20. https://doi.org/10.1158/0008-5472.CAN-06-0369
  11. Leonard GD, Reilly EM (2004). Post-operative chemotherapy improves disease-free survival, but not overall survival in people with oesophageal squamous cell carcinoma. Cancer Treat Rev, 30, 473-7. https://doi.org/10.1016/j.ctrv.2004.05.007
  12. Lu YF, Liu ZC, Li ZH, et al (2014). Esophageal/gastric cancer screening in high-risk populations in Henan Province, China. Asian Pac J Cancer Prev, 15, 1419-22. https://doi.org/10.7314/APJCP.2014.15.3.1419
  13. Mariette C, Piessen G, Triboulet JP (2007). Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol, 8, 545-53. https://doi.org/10.1016/S1470-2045(07)70172-9
  14. Mirinezhad SK, Jangjoo AG, Seyednejad F, et al (2014). Impact of tumor length on survival for patients with resected esophageal cancer. Asian Pac J Cancer Prev, 15, 691-4. https://doi.org/10.7314/APJCP.2014.15.2.691
  15. Miyagawa K, Sakakura C, Nakashima S, et al (2006). Down-regulation of RUNX1, RUNX3 and CBFbeta in hepatocellular carcinomas in an early stage of hepatocarcinogenesis. Anticancer Res, 26, 3633-43.
  16. Ogino S, Meyerhardt JA, Kawasaki T, et al (2007). CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch, 450, 529-37. https://doi.org/10.1007/s00428-007-0398-3
  17. Ozcelik B, Turkyilmaz C, Ozgun MT, et al (2010). Prevention of paclitaxel and cisplatin induced ovarian damage in rats by a gonadotropin-releasing hormone agonist. Fertility Sterility, 93, 1609-14. https://doi.org/10.1016/j.fertnstert.2009.02.054
  18. Raspagliesi F, Zanaboni F, Martinelli F, et al (2014). Role of paclitaxel and cisplatin as the neoadjuvant treatment for locally advanced squamous cell carcinoma of the vulva. J Gynecol Oncol, 25, 22-9. https://doi.org/10.3802/jgo.2014.25.1.22
  19. Song W, Tang Z, Li M, et al (2014). Polypeptide-based combination of paclitaxel and cisplatin for enhanced chemotherapy efficacy and reduced side-effects. Acta Biomaterialia, 10, 1392-402. https://doi.org/10.1016/j.actbio.2013.11.026
  20. Sugiura H, Ishiguro H, Kuwabara Y, et al (2008). Decreased expression of RUNX3 is correlated with tumor progression and poor prognosis in patients with esophageal squamous cell carcinoma. Oncol Rep, 19, 713-9.
  21. Suzuki M, Shigematsu H, Shames DS, et al (2005). DNA methylation associated inactivation of TGF beta-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancers. Br J Cancer, 93, 1029-37. https://doi.org/10.1038/sj.bjc.6602837
  22. Tadasuke Hashiguchi, Motomi Nasu, Takashi hashimoto, et al (2014). Docetaxel, cisplatin and 5-fluorouracil adjuvant chemotherapy following three-field lymph node dissection for stage II/III N1, 2 esophageal cancer. Molecular Clin Oncol, 2, 719-24.
  23. Tonomoto Y, Tachibana M, Dhar D.K, et al (2007). Differential expression of RUNX genes in human esophageal squamous cell carcinoma: downregulation of RUNX3 worsens patient prognosis. Oncol, 73, 346-56. https://doi.org/10.1159/000135350
  24. Wongpaiboonwattana W, Tosukhowong P, Dissayabutra T, et al (2013). Oxidative stress induces hypomethylation of LINE-1 and hypermethylation of the RUNX3 promoter in a bladder cancer cell line. Asian Pac J Cancer Prev, 14, 3773-8. https://doi.org/10.7314/APJCP.2013.14.6.3773
  25. Yan C, Kim YW, Ha YS, et al (2012). RUNX3 methylation as a predictor for disease progression in patients with nonmuscle-invasive bladder cancer. J Surg Oncol, 105, 425-30. https://doi.org/10.1002/jso.22087

Cited by

  1. 5-Azacytidine suppresses EC9706 cell proliferation and metastasis by upregulating the expression of SOX17 and CDH1 vol.38, pp.4, 2016, https://doi.org/10.3892/ijmm.2016.2704